Seer appoints Nicolas Roelofs to board as Lead Independent Director effective Aug 13, 2024

Seer, Inc.

Roelofs replaces David Hallal as Lead Independent Director and joins CG&N and Science & Technology committees.
Initial equity award of 69,470 stock options and 46,886 RSUs, vesting in three equal annual installments.
Roelofs brings 35+ years experience including president of Agilent Life Sciences Group.
No arrangement or understanding with any person regarding his election as director.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Nicolas Henry Roelofs

Lead Independent Director

SEER · Seer, Inc.

Effective: 2024-08-13
Filed: August 16, 2024, 7:59 PM ET

On August 13, 2024, the board of directors (the “Board”) of Seer, Inc. (the “Company”) appointed Nicolas Henry Roelofs, Ph.D. to the Board with a term expiring at the Company’s 2025 annual meeting of the stockholders.

Role change

David Hallal

Lead Independent Director

SEER · Seer, Inc.

Effective: 2024-08-13
Successor: Nicolas Henry Roelofs
Filed: August 16, 2024, 7:59 PM ET

The Company also announced that Dr. Roelofs would replace David Hallal as the Company’s Lead Independent Director and would serve on the Company’s Corporate Governance and Nominating Committee and Science and Technology Committee.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Nicolas Henry Roelofs was appointed as Lead Independent Director at Seer, Inc..

Action: appointed
Role: Lead Independent Director

Exact text from the filing

On August 13, 2024, the board of directors (the “Board”) of Seer, Inc. (the “Company”) appointed Nicolas Henry Roelofs, Ph.D. to the Board with a term expiring at the Company’s 2025 annual meeting of the stockholders.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

David Hallal changed role as Lead Independent Director at Seer, Inc..

Action: replaced
Role: Lead Independent Director

Exact text from the filing

The Company also announced that Dr. Roelofs would replace David Hallal as the Company’s Lead Independent Director and would serve on the Company’s Corporate Governance and Nominating Committee and Science and Technology Committee.

View on SEC.gov

Seer, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-098074

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.